Erratum to Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease (Clin J Am Soc Nephrol, 2011, 6, 2374-2383, 10.2215/CJN.01720211);Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 10, 2011, Pages 2374-2383

  Schepers, Eva ^a   Barreto, Daniela V ^b,c   Liabeuf, Sophie ^b,c   Glorieux, Griet ^a   Eloot, Sunny ^a   Barreto, Fellype C ^b,c   Massy, Ziad ^b,c   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b INSERM   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; ACETYLCYSTEINE; C REACTIVE PROTEIN; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG USE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MONOCYTE; PROTEIN EXPRESSION;

EID: 80053909035     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02620312     Document Type: Erratum

References (59)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-S119, 1998
2. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R: The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 28: 478-483, 2007
3. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20: 1048-1056, 2005
4. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3: 505-521, 2008
5. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
6. Cooke JP: Asymmetrical dimethylarginine: The Uber marker? Circulation 109: 1813-1818, 2004
7. Kielstein JT, Tsikas D, Fliser D: Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 62: 39-44, 2006
8. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, Marz W: Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 53: 273-283, 2007
9. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frö lich J, Bö ger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113-2117, 2001
10. Kiechl S, Lee T, Santer P, Thompson G, Tsimikas S, Egger G, Holt DW, Willeit J, Xu Q, Mayr M: Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 205: 261-265, 2009
11. Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Boehm BO, Winkelmann BR, März W: Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: The Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 57: 112-121, 2011
12. Schulze F, Carter AM, Schwedhelm E, Ajjan R, Maas R, von Holten RA, Atzler D, Grant PJ, Böger RH: Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 208: 518-523, 2010
13. Zeller M, Korandji C, Guilland JC, Sicard P, Vergely C, Lorgis L, Beer JC, Duvillard L, Lagrost AC, Moreau D, Gambert P, Cottin Y, Rochette L: Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol 28: 954-960, 2008
14. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R: Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 24: 1429-1435, 2008
15. Bode-Bö ger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, Reinecke H: Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 17: 1128-1134, 2006
16. Closs EI, Basha FZ, Habermeier A, Forstermann U: Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1: 65-73, 1997
17. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63: 1934-1943, 2003
18. Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J, Lameire N, De Deyn P, Vanholder R: In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 65: 2184-2192, 2004
19. Eperon S, Jungi TW: The use of human monocytoid lines as indicators of endotoxin. J Immunol Methods 194: 121-129, 1996
20. Kim SH, Kang SN, Kim HJ, Kim TS: Potentiation of 1,25-dihydroxyvitamin D(3)-induced differentiation of human promyelocytic leukemia cells into monocytes by costunolide, a germacranolide sesquiterpene lactone. Biochem Pharmacol 64: 1233-1242, 2002
21. Sokoloski JA, Sartorelli AC: Induction of the differentiation of HL-60 promyelocytic leukemia cells by nonsteroidal anti-inflammatory agents in combination with low levels of vitamin D3. Leuk Res 22: 153-161, 1998
22. Foulds S: Novel flow cytometric method for quantifying nuclear binding of the transcription factor nuclear factor kappa B in unseparated human monocytes and polymorphonuclear cells. Cytometry 29: 182-186, 1997
23. Barreto DV, Barretto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, Choukroun G, Vanholder R, Massy Z: Plasma IL-6 is independently associated with mortality in both hemodialysis and pre-dialysis CKD patients. Kidney Int 77: 550-556, 2009
24. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD, Zhang YL, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51: 395-406, 2008
25. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1-S266, 2002
26. Sadowska AM, Keenoy B, Vertongen T, Schippers G, Radomska- Lesniewska D, Heytens E, De Backer WA: Effect of N-acetylcysteine on neutrophil activation markers in healthy volunteers: In vivo and in vitro study. Pharmacol Res 53: 216-225, 2006
27. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999
28. Libby P: Inflammation in atherosclerosis. Nature 420: 868-874, 2002
29. Baeuerle PA, Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12: 141-179, 1994
30. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: Sources, consequences, and therapy. Semin Dial 15: 329-337, 2002
31. Schepers E, Glorieux G, Dou L, Cerini C, Gayrard N, Louvet L, Maugard C, Preus P, Rodriguez-Ortiz M, Argiles A, Brunet P, Cohen G, Jankowski J, Jankowski V, Massy Z, Rodriguez M, Vanholder R: Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: An in vitro evaluation. Blood Purif 30: 277-287, 2010
32. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berlund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999
33. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J: Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 19: 593-599, 2008
34. Oner-Iyidogan Y, Oner P, Kocak H, Gurdol F, Bekpinar S, Unlucerci Y, Caliskan Y, Cetinalp-Demircan P, Kocak T, Turkmen A: Dimethylarginines and inflammation markers in patients with chronic kidney disease undergoing dialysis. Clin Exp Med 9: 235-241, 2009
35. Caglar K, Yilmaz MI, Sommez A, Cakir E, Kaya A, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Bilgi C, Oktenli C, Vural A, Zoccali C: ADMA, proteinuria and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 70: 781-787, 2006
36. Zoccali C, Maas R, Cutrupi S, Pizzini P, Finocchiaro P, Cambareri F, Panuccio V, Martorano C, Schulze F, Enia G, Tripepi G, Böger R: Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transplant 22: 801-806, 2007
37. Kielstein JT, Salpeter SR, Bode-Bö ger SM, Cooke JP, Fliser D: Symmetric dimethylarginine (SDMA) as endogenous marker of renal function: A meta-analysis. Nephrol Dial Transplant 21: 2446-2451, 2006
38. Tutarel O, Denecke A, Bode-Böger SM, Martens-Löbenhoffer J, Schieffer B, Westhoff-Bleck M, Kielstein JT: Symmetrical dimethylarginine outperforms CKD-EPI and MDRD-derived eGFR for the assessment of renal function in patients with adult congenital heart disease. Kidney Blood Press Res 34: 41-45, 2010
39. Nijveldt RJ, Teerlink T, Van Der Hoven B, Siroen MPC, Kuik DJ, Rauwerda JA, Van Leeuwen PAM: Asymmetrical dimethylarginine (ADMA) in critically ill patients: High plasma ADMA concentration is an independent risk factor of ICU mortality. Clinical Nutrition 22: 23-30, 2003
40. Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drueke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R: Inconsistency of reported uremic toxin concentrations. Artif Organs 31: 600-611, 2007
41. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Bö ger R: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 13: 490-496, 2002
42. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progresssion of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 16: 2456-2461, 2005
43. Anderstam B, Katzarski K, Bergstrom J: Serum levels of NG, NGdimethyl- L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 8: 1437-1442, 1997
44. Clarke S: Protein methylation. Curr Opin Cell Biol 5: 977-983, 1993
45. Teerlink T: ADMA metabolism and clearance. Vasc Med 10[Suppl 1]: S73-S81, 2005
46. Leiper JM: The DDAH-ADMA-NOS pathway. Ther Drug Monit 27: 744-746, 2005
47. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459, 2003
48. Kielstein JT, Bö ger RH, Bode-Bö ger SM, Martens-Löbenhoffer J, Lonnemann G, Frölich JC, Haller H, Fliser D: Low dialysance of asymmetric dimethylarginine (ADMA): In vivo and in vitro evidence of significant protein binding. Clin Nephrol 62: 295-300, 2004
49. Kalousova M, Kielstein JT, Hodkova M, Zima T, Dusilova- Sulkova S, Martens-Löbenhoffer J, Bode-Böger SM: No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood Purif 24: 439-444, 2006
50. Grooteman MP, Wauters IM, Teerlink T, Twisk JW, Nube MJ: Plasma dimethylarginine levels in chronic hemodialysis patients are independent of the type of dialyzer applied. Blood Purif 25: 281-289, 2007
51. Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W: Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes. Kidney Int Suppl 78: S19-S24, 2001
52. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drüeke T, Santangelo F, Descamps-Latscha B: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 64: 82-91, 2003
53. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 107: 992-995, 2003
54. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343: 180-184, 2000
55. Tepel M, Zidek W: N-Acetylcysteine in nephrology: Contrast nephropathy and beyond. Curr Opin Nephrol Hypertens 13: 649-654, 2004
56. Safirstein R, Andrade L, Vieira JM: Acetylcysteine and nephrotoxic effects of radiographic contrast agents-a new use for an old drug. N Engl J Med 343: 210-212, 2000
57. Krane V, Krieter DH, Olschewski M, Marz W, Mann JF, Ritz E, Wanner C: Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 49: 267-275, 2007
58. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaille A, Cobbe SM, Gronhagen- Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
59. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63: 793-808, 2003